Adimmune Corporation (4142) announced that in response to the emerging variants of SARS-CoV-2 and the trend of COVID-19 being rendered into just another seasonal coronavirus (JASC), the company is developing a next generation of vaccines against SARS-CoV-2 and variants as well as commencing clinical trial overseas.
On account of the mutations of SARS-CoV-2 and the prevalence of COVID-19, Adimmune underlined that it is crucial to develop next generation vaccines for the continuing needs to fight against COVID-19. Adimmune has readjusted its strategies for vaccine development and will track the mutations of the virus strains for developing the next generation of vaccines, which is designed to prevent the current dominant variant strains and possible mutations in the future. Adimmune is determined to battle against the pandemic.
Driven by the resolve to safeguard public health in Taiwan, Adimmune was the first corporation in Taiwan to engage in COVID-19 vaccine research and development in the beginning of the outbreak in early 2020, and the entire staff has worked tirelessly since 2020. The company adjusted the effective dosages following the phase I clinical trial of its first generation of COVID-19 vaccines to meet the authority’s requirement, and submitted the application for the clinical program to determine the effective dosages, which was not approved by the authority. Even so, Adimmune is continuing the discussions with the regulatory authorities and is ready to carry out the phase II clinical trial overseas. Adimmune is confident and determined to finish the phase II and III clinical trials of COVID-19 overseas and the company’s commitment in developing and producing the COVID-19 vaccines remains unchanged.